Aeterna Zentaris Inc. (NASDAQ:AEZS)
Aeterna Zentaris Inc. (NASDAQ:AEZS), declared that 1,906,451 Series B Common Share Purchase Warrants remained outstanding and that there were about 632.7 million Common Shares issued and outstanding at the close of business on November 11, 2015.
David A. Dodd, Chairman, President and Chief Executive Officer of the Company explained, “The holders of Series B Warrants who agreed on November 1, 2015 to exercise all of the about 4.1 million Series B Warrants then held by them have now exercised 2,270,638 of such Series B Warrants. There remain outstanding 1.1 million Series B Warrants held by one of the holders who is a party to the November 1 agreement and 806,451 Series B Warrants held by a holder who did not become a party to the November 1 agreement. At the conversion ratio specified in the November 1 agreement the 1.1 million Series B Warrants held by the participating warrantholder will, upon their exercise, result in the issuance of about 36.5 million additional common shares. By extinguishing these Series B Warrants and with our forthcoming share consolidation, we anticipate an improved capital structure that will provide the necessary basis to successfully build shareholder value as we proceed toward the completion of our pivotal, phase 3 program for Zoptrex™, which recently received the DSMB recommendation to proceed to completion, in addition to the completion of the confirmatory trial for Macrilen™ and, our anticipated continued improvement in revenue contribution from our current and anticipated additional commercial activities.”
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
JD.Com Inc (ADR) (NASDAQ:JD)
On Thursday, JD.Com Inc (ADR) (NASDAQ:JD)’s shares inclined 3.23% to $28.78.
JD has the market capitalization of $38.28 billion. The stock has P/B ratio of -6.80 while EPS was $-0.21. Institutional ownership of the company was 1.08% while 2.74 million shares were outstanding. Net profit margin of the Company was -1.30% while its gross profit margin was 12.50%. Share of the company moved above its SMA 50 with 8.01%. ROE ratio was -4.90% while ROI was -14.80%.
The mean estimate for the short term price target for JD.Com Inc (ADR) (JD) stands at $37.74 according to 25 Analysts. The higher price target estimate for the stock has been calculated at $47.17 while the lower price target estimate is at $28.42.
Analysts mean recommendation for the stock is 2.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
JD.com, Inc. is an online direct sales company. The Company engages primarily in the sale of electronics and home appliance products and general merchandise products (including audio, video products and books) sourced from manufacturers, distributors and publishers in People’s republic of China (PRC) on the Internet through its Website jd.com. I
China Life Insurance Company Ltd. (ADR) (NYSE:LFC)
China Life Insurance Company Ltd. (ADR) (NYSE:LFC)’s shares gained 0.78% to $18.07.
LFC Its past 5-day performance at 0.11% . So far in 2015, the company has a year-to-date performance of 84.76%. The stock, as of last close, traded 23.85% up from its 52 week low and was -31.27% below its 52 week high. Its latest closing price was -12.17% below the SMA200 while the distance from SMA 50 and SMA 20 was -0.52% and -3.97% respectively.
The mean estimate for the short term price target for China Life Insurance Company Ltd. (ADR) (LFC) stands at $23.14 according to 2 Analysts. The higher price target estimate for the stock has been calculated at $23.20 while the lower price target estimate is at $23.08.
Analysts mean recommendation for the stock is 1.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
China Life Insurance Company Limited is a life insurance company. The Company and its subsidiaries are principally engaged in providing individual and group life insurance, annuity products, and accident and health insurance in China.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
At the end of Thursday’s trade, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)‘s shares dipped -2.59% to $12.79.
LXRX has market capitalization of $1.35 billion. Its current ratio was 7.20 while its shares were above its 50 days simple moving average with 8.77%. The company offered earning per share of $-0.92 while its 103.62 million shares were outstanding. YTD performance of the company was 100.81%. Stock volatility for the week was 9.11% while for the month it was shown at 7.93%.
The mean estimate for the short term price target for Lexicon Pharmaceuticals, Inc. (LXRX) stands at $24.00 according to 3 Analysts. The higher price target estimate for the stock has been calculated at $26.00 while the lower price target estimate is at $21.00.
Analysts mean recommendation for the stock is 2.40. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates:
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.